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The endothelial barrier strictly maintains vascular and tissue homeostasis, and therefore
modulates many physiological processes such as angiogenesis, immune responses, and
dynamic exchanges throughout organs. Consequently, alteration of this finely tuned func-
tion may have devastating consequences for the organism. This is particularly obvious in
cancers, where a disorganized and leaky blood vessel network irrigates solid tumors. In
this context, vascular permeability drives tumor-induced angiogenesis, blood flow distur-
bances, inflammatory cell infiltration, and tumor cell extravasation.This can directly restrain
the efficacy of conventional therapies by limiting intravenous drug delivery. Indeed, for more
effective anti-angiogenic therapies, it is now accepted that not only should excessive angio-
genesis be alleviated, but also that the tumor vasculature needs to be normalized. Recovery
of normal state vasculature requires diminishing hyperpermeability, increasing pericyte
coverage, and restoring the basement membrane, to subsequently reduce hypoxia, and
interstitial fluid pressure. In this review, we will introduce how vascular permeability accom-
panies tumor progression and, as a collateral damage, impacts on efficient drug delivery.
The molecular mechanisms involved in tumor-driven vascular permeability will next be
detailed, with a particular focus on the main factors produced by tumor cells, especially
the emblematic vascular endothelial growth factor. Finally, new perspectives in cancer ther-
apy will be presented, centered on the use of anti-permeability factors and normalization
agents.
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VASCULAR PERMEABILITY IN CANCERS
VASCULAR BARRIER ORGANIZATION
Endothelial cells, pericytes, smooth muscle cells, and the basal
membrane collectively form the blood vascular wall, which ensures
selective exchanges between plasma and irrigated tissues. The pas-
sage of macromolecules, fluids, and cells through this endothelial
barrier can occur either through (transcellular) or between cells
(paracellular) (1). The ability to pass from the interstitial space to
the blood compartment, and vice versa depends on charge, size,
and binding characteristics.
Small molecules (inferior to 3 nm) are commonly transported
by the transcellular route, which requires a system of trafficking
vesicles, called vesicular vacuolar organelles (VVOs) (Figure 1).
Several permeability factors, such as vascular endothelial growth
factor (VEGF) and histamine have been demonstrated to acti-
vate VVOs and to orchestrate vascular homeostasis (2). These
VVOs comprise, among other things, clustered caveolae, and rely
on caveolin-1 protein function, that notably guarantees albumin
transport. Interestingly, caveolin-1 plays a dual regulatory role in
microvascular permeability by stabilizing caveolae structures and
allowing caveolar transcytosis, while acting as a negative regulator
through endothelial nitric oxide synthase (eNOS) (3, 4).
Cells and macromolecules larger than 3 nm use the paracellu-
lar pathway, which is mediated by the coordinated opening and
closing of endothelial cell–cell junctions. Adherens (AJ) and tight
(TJ) junctions maintain the restrictiveness of the barrier, while
gap junctions connect adjacent endothelial cells. Gap junctions
are responsible for water and ion transport but do not contribute
significantly or directly to the establishment of vascular barriers
(Figure 1). Among AJ proteins, the most important is vascular
endothelial cadherin (VE-cadherin),which is exclusively expressed
in vessels (1, 5). In mice, VE-cadherin gene deletion results in early
embryonic lethality due to massive vascular defects, while loss of its
function provokes a hyperpermeability phenotype in adults (6, 7).
VE-cadherin comprises five immunoglobulin-like domain repeats
in its extracellular region, one single-pass transmembrane domain
and a short cytoplasmic tail. While the extracellular domain con-
fers Ca++ dependency and allows homophilic interaction in trans
(i.e., between cadherins on neighboring cells), the transmem-
brane domain participates in lateral clustering within the same
cell (cis) (8). The cytoplasmic part of VE-cadherin binds to pro-
teins from the armadillo-repeat gene family, namely p120-catenin
and either β-catenin or plakoglobin (γ-catenin). This complex
serves to strengthen adhesion forces and allows dynamic con-
tacts (Figure 2). p120-catenin interacts with the juxtamembrane
part of the VE-cadherin cytoplasmic domain and is involved in
its retention at the cell surface, while β/γ-catenins, on the other
hand, act as constitutive partners of VE-cadherin, bound to its
carboxy-terminal part (9, 10). Importantly, VE-cadherin is also
connected to the actin cytoskeleton through the actin-binding
protein, α-catenin (5). Other adhesive proteins that accumulate in
or close to AJ, include N-cadherin, platelet-endothelial cell adhe-
sion molecule (PECAM-1), and junctional adhesion molecules
(JAMs).
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FIGURE 1 |Transcellular and paracellular pathways in endothelial cells. The passage of cells and macromolecules through the endothelial barrier can occur
through transcellular (vesicular vacuolar organelles) or paracellular (tight and adherens junctions) pathways. Gap junctions ensure water and ion transport.
Moreover, endothelial cells are anchored and connected to the extracellular matrix (ECM) through integrin-based adhesion complexes, namely focal adhesions.
p120 
-cat 
-cat 
Actin 
plako 
Extracellular  
domain  
Transmembrane domain  
Intracellular  
domain  
VEGF-R2 
VE-PTP 
VE-cadherin 
-cat 
-cat 
FIGURE 2 |VE-cadherin adhesive complex. VE-cadherin mediates the
adhesion between endothelial cells in calcium-dependent manner.
VE-cadherin is constituted of an extracellular domain, which allows homophilic
interaction in trans. The transmembrane domain participates to lateral
clustering in cis.The intracellular domain of VE-cadherin binds p120-catenin
(p120), and β-catenin (β-cat), which participates to VE-cadherin membrane
retention. Actin cytoskeleton is anchored to VE-cadherin via α-catenin (α-cat)
or plakoglobin (plako). In addition, VE-cadherin can bind VEGF-R2 (vascular
endothelial growth factor receptor 2) and VE-PTP (vascular endothelial
phosphotyrosine phosphatase).
Tight junctions participate in endothelial cell cohesion and
block molecule diffusion along the apical and basolateral poles
(11). They rely on transmembrane adhesion proteins (occludin
and claudins), JAM family proteins, and intracellular con-
nectors, including ZO-1, -2, -3 (Zonula Occludens). First,
occludin and claudins contain four transmembrane domains with
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N- and C-terminal intracellular parts. Second, JAM-A belongs
to the immunoglobulin superfamily with one intracellular short
domain, one single transmembrane domain, and two extracellu-
lar immunoglobulin-like domains. Third, the ZO proteins contain
three PDZ (post synaptic density protein PSD95, Drosophila disk
large tumor suppressor Dlg1, and zonula occludens-1 protein
zo-1), one SH3 (SRC homology 3) and one guanylyl kinase-like
domains (11). Contrary to VE-cadherin, deletion of the claudin-5
gene does not impair mouse embryo development, but rather leads
to post-natal death caused by a defective blood-brain barrier (12).
Thus, VE-cadherin is instrumental in vascular barrier integrity,
while claudins may have a more restrictive role (13). Neverthe-
less AJ and TJ are functionally and structurally linked and can
influence each other (14, 15).
Within blood vessels, endothelial cells are interactively
anchored to the extracellular matrix (ECM) through integrin-
based adhesion complexes, namely focal adhesions (Figure 1).
Indeed, integrins bridge the ECM to the acto-myosin contractility
apparatus (16), and allow endothelial cells to adapt to extracellular
signals and cues (e.g., shear stress and secreted molecules). From
a molecular standpoint, Rho-GTPase activation, stress fiber for-
mation, and acto-myosin contraction are finely tuned through
integrin adhesion and collectively contribute to the modula-
tion of endothelial junction integrity (17, 18). More recently,
it was demonstrated that the integrin-associated focal adhesion
tyrosine kinase (FAK) contributes to the impairment of vascu-
lar barrier function (19). Indeed, VEGF-induced FAK activation
was shown to lead to VE-cadherin/FAK interaction in associa-
tion with β-catenin phosphorylation on tyrosine Y142, result-
ing in VE-cadherin/β-catenin dissociation, junction opening, and
endothelial barrier disruption.
Hence, vascular barrier properties depend on both structural
(basal membrane, smooth muscle cells, endothelial cells) and func-
tional (VVO, AJ, TJ) features. To endorse this role, endothelial
cell adhesion has to be tightly regulated. Indeed, aberrant and
uncontrolled increase of vascular permeability can participate
in the progression of many pathological states, such as chronic
inflammatory diseases, diabetes, and tumor angiogenesis.
VASCULAR LEAKAGE IN THE TUMOR MICROENVIRONMENT
Compared to normal tissues, tumor vasculature is immature and
exhibits structural abnormalities, such as dilatation, saccular for-
mation, and a hyper-branched and twisted pattern. Moreover,
solid tumors usually present few to none functional lymphatic
vessels (20, 21). Many molecular and cellular factors contribute
to this morphological and functional failure, in which vascular
permeability is central. Rapidly growing tumors secrete an abun-
dance of different factors (VEGF, chemokines, and others) that
govern uncontrolled angiogenesis. In such microenvironments,
most of the criteria that define the endothelial barrier properties
are circumvented.
First, tumor vessels are characterized by extensive angiogene-
sis, i.e., neovessel formation from pre-existing vascular networks.
In this scenario, tumor endothelial cells have a proliferation rate
50–200 times faster than that of normal quiescent endothelial cells
(22). They also have to migrate and rearrange into vascular tubules,
dedicated to fuel the tumor mass. This high endothelial plasticity in
the constantly remodeled vascular wall is accompanied by elevated
permeability. Tumor vessel hyperpermeability correlates with faint
VE-cadherin expression, opening of paracellular junctions, and
transcellular holes formation (23). In the course of tumor growth,
the direct consequence of hyperpermeable vessels is plasma
membrane protein extravasation and formation of a provisory
matrix to allow endothelial cell sprouting and formation of new
vessels (24).
Morphologically, the pericytes surrounding tumor vessels are
abnormally shaped and are weakly associated with endothelial
cells (25). In addition, tumor blood vessels lack smooth muscles
(Figure 3). Similarly, the basal membrane can be either unusu-
ally thick or totally absent (26). In these conditions, resistance to
blood flow is increased, and thereby the efficacy in tumor blood
supply is reduced. As a consequence, despite a high microvessel
density, tumors are poorly vascularized with hyperpermeable vas-
culature. This could lead in fine to the accumulation of metabolic
products (lactic and carbonic acids) and extracellular pH decrease
(27). Tumor vessel defects also quell oxygen supply, frequently
causing hypoxia in the tumor microenvironment. Hypoxia, in
turn, supports tumor angiogenesis through the hypoxia-inducible
transcription factors (HIF), and further elevates the expression of
pro-angiogenic molecules, such as VEGF, TNF (tumor necrosis
factor), and PDGF (platelet-derived growth factor). Interestingly,
because of its involvement in chemo- and radio-resistance, as well
as metastasis, hypoxia has been suggested as an adverse prognostic
factor (28).
Within the tumor microenvironment, the ECM undergoes sig-
nificant compositional modifications most notably by increasing
the levels of expression of collagen-1, matrix metalloproteases
(MMP)-1 and -2, and laminin-5 (29). For instance, collagen-
1 deposit increases ECM stiffness, and this is related with
poor prognosis and higher metastasis potential (30). In addi-
tion, ECM stiffness enhances integrin expression and promotes
focal adhesion signaling, and consequently influences tumor cell
malignancy (31).
In summary, abnormal blood vessels and lack of lymphatic ves-
sels in tumors, as well as increased ECM stiffness and relatively high
interstitial fluid pressure (IFP) collectively contribute to the func-
tional outcome called enhanced permeability and retention (EPR).
This phenomenon facilitates both macromolecule extravasation
and retention. Whereas normal vessels form a selective barrier,
limiting cell and macromolecule passage, the tumor vasculature
is extremely leaky and not restrictive. Consequently, although
these features could benefit to tumor angiogenesis and growth,
anti-tumor drug delivery is rather limited.
IMPACT ON DRUG DELIVERY
To gain in bioavailability and selectivity toward tumor cells, thera-
peutic molecules must counteract biological and physical barriers,
among which are endothelial transport and blood flow. Drug efflux
pumps are one of the main obstacles that anti-cancer drugs must
overcome. These transporters are highly expressed in a large panel
of cancer cells, as well as in the blood-brain barrier, where they
ensure drug detoxification (32, 33).
However, tumor vessels cannot ensure correct tumor blood per-
fusion, since they are structurally aberrant and hyperpermeable
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FIGURE 3 | Endothelial barrier in normal and tumor vessels. The
endothelial barrier structure differs in normal (A) and tumor (B) blood vessels.
Contrary to normal vessels, the tumor vasculature pattern is extremely
disorganized and anarchic, presents morphological and structural difference,
i.e., weak association between endothelial cells, abnormal shapes of
pericytes, lack of smooth muscles, as well as basal membrane modification.
(24). The pressure difference between vessels and surrounding
tissues constitutes also an important physical barrier. Upon vas-
cular leakage, transcapillary interstitial fluid flow decreases and
IFP increases resulting in poor drug penetration through tumor
vessels (21). In addition to blood vessel leakage, both the absence
of a functional lymphatic system and increased ECM-frictional
resistance also lead to tumor IFP increase (34). This ultimately
provokes disruption in blood flow directions, again limiting drug
delivery.
Importantly, tumor drug delivery can be tailored by changing
the size and charge of the delivered molecule. Of interest, mole-
cules larger than 40 kDa cannot be passively eliminated through
renal clearance and are unable to cross normal blood vessels
through endothelial junctions; however, they could easily pene-
trate tumors through leaky vessels. EPR of tumor vessels permits
the passage of molecules ranging from 40 to 70 kDa, thus, in associ-
ation with other properties such as the ability to traverse relatively
long distances,prolonged plasma half-life and slow clearance, these
larger molecule have been proposed to be the most appropriate for
specific tumor delivery (35, 36). In addition, due to the negative
charges of the vessel luminal face, the use of cationic therapeutic
molecules may also favor vascular accumulation, which in turn
can elevate tumor drug concentration (37).
Thus, although drug delivery is strongly impaired in tumors
because of structural and functional vascular defects, some of these
constraints, such as vessel leakiness, can be exploited for curative
purposes.
MOLECULAR MECHANISMS INVOLVED IN VASCULAR
PERMEABILITY
As presented above, endothelial barrier integrity ensures vascular
and tissue homeostasis. In cancers, deregulation of this fine-tuned
function leads to the formation of a chaotic blood vessel network
associated with elevated permeability. We will now detail the mole-
cular mechanisms involved in tumor-driven vascular permeability,
focusing on the main factors produced by tumor cells, such as
VEGF and chemokines. This knowledge could open new avenues
for drug design.
VASCULAR ENDOTHELIAL GROWTH FACTOR
Vascular endothelial growth factor belongs to the family of
platelet-derived growth factors and was originally referred to as
vascular permeability factor (38). It is a homodimeric glycopro-
tein of which several forms have been described in mammals, these
are: VEGF-A, B, C, D, and the placenta growth factor PlGF. Among
these,VEGF-A is the most commonly studied and better described
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in literature. Various cell types, such as endothelial cells, smooth
muscle cells, fibroblasts, and immune cells (macrophages, lym-
phocytes, neutrophils, and eosinophils) can produce and release
VEGF within the environment. In turn, VEGF can act in both an
autocrine and paracrine manner. In cancers, tumor cells consti-
tute an important source of VEGF. VEGF stimulates endothelial
cell growth and promotes vasculogenesis and angiogenesis. It also
increases vascular permeability, its first described function, in
many tissues, and plays a crucial role in tumor vasculature devel-
opment (22). VEGF intracellular signaling is mediated by three
tyrosine kinase-receptors, namely VEGF-R1, -R2, and -R3, as well
as co-receptors such as neuropilins. The binding of the ligand to
its cognate receptors induces their dimerization, autophosphory-
lation, and subsequent signal transduction (39). VEGF-A inter-
acts with both VEGF-R1 and -R2, but only VEGF-R2 is directly
involved in normal and pathological vascular permeability (40).
However, VEGF-R1 is reported to act as a regulator of VEGF-R2
signaling, and thus might indirectly regulate vascular permeability.
VEGF-A promotes vascular permeability by disruption of AJ
and TJ, resulting in transient opening of endothelial cell–cell
contacts (5, 14) (Figure 4). Indeed, VEGF-A promotes tyrosine
phosphorylation of VE-cadherin and of its binding partners β-
catenin, plakoglobin, and p120, in a Src-dependent mechanism
(41). Consistent with this, VE-cadherin phosphorylation is inhib-
ited in Src-deficient mice (41). VE-cadherin can also associate
with VEGF-R2 and inhibit its phosphorylation and subsequent
internalization (42). This association potentiates the phospho-
rylation of AJ components by Src, thus impairing endothelial
barrier integrity and favoring tumor cell extravasation and dissem-
ination in pathological models (43). The VE-cadherin/VEGF-R2
association also contributes to VE-cadherin-induced contact inhi-
bition of cell growth and requires the β-, but not p120-catenin,
binding domain of VE-cadherin (42, 44). In addition, VEGF-A
mediates VE-cadherin phosphorylation and internalization via
the sequential activation of Src, the guanine nucleotide exchange
factor Vav2, the Rho-GTPase Rac, and its downstream effector,
the serine-threonine kinase PAK (Figure 4). This signaling path-
way culminates in the PAK-dependent phosphorylation of VE-
cadherin, which directs its internalization (45). Moreover, VEGF
signaling decreases VE-cadherin/p120-catenin association pro-
moting clathrin-dependentVE-cadherin endocytosis (46). Indeed,
p120 binding to VE-cadherin prevents its internalization, while
its silencing by siRNA leads to VE-cadherin degradation, and
loss of cell–cell contacts (10, 47). The expression of VE-cadherin
mutants that compete with the endogenous molecule for binding
with p120, triggers VE-cadherin degradation, suggesting that p120
might act as plasma membrane retention signal. More recently,
a motif within VE-cadherin was identified to be responsible for
VE-cadherin/p120 coupling and endocytosis sorting (48). In this
context, VE-cadherin-mediated cell–cell contacts are stabilized
by the small GTPase Rap1 and its effector, the cyclic adeno-
sine monophosphate (cAMP)-activated guanidine exchange factor
Epac (49, 50). Small GTPases also regulate myosin light chain
(MLC) phosphorylation, acto-myosin contractility, and endothe-
lial permeability (51). Indeed, VEGF induces the phosphorylation
of MLC that results in the formation of stress fibers which exert
centripetal tension on intercellular junctions (52).
Of note, endothelial permeability can also be regulated through
changes in the expression of AJ and TJ components (15, 53). For
example, VEGF signaling through VEGF-R2 induces the expres-
sion of SRF (serum response factor), which is important for
VE-cadherin expression (54). Indeed, SRF knockdown in mice
reduces VE-cadherin expression and angiogenesis. Furthermore,
claudin-5 expression is regulated by VE-cadherin, confirming that
the latter is instrumental in controlling endothelial barrier func-
tion (15). Recently, it has been described that VEGF is involved in
claudin-5 down-regulation in peritoneal endothelium, inducing
ascites in ovarian cancer patients (55).
INTERLEUKIN-8
Cytokines are key drivers of immune responses and play impor-
tant roles in cancer progression. Among these, the chemokine
IL-8 (CXCL8, CXC chemokine ligand 8) is overexpressed and
secreted by cancerous cells. Of note, their cognate G-protein-
coupled receptors (GPCR), CXCR1 and CXCR2, are expressed on
endothelial cells, tumor cells, and neutrophils/tumor-associated-
macrophages, indicative of pleiotropic activities of IL-8. Activation
of IL-8 endothelial receptors is known to promote angiogenic
responses, through enhanced proliferation, survival, and migra-
tion (56). Furthermore, intratumoral IL-8 concentration is pro-
posed to chiefly cause neutrophil recruitment into the tumor
microenvironment and to promote metastasis (57). Besides its
chemotactic role, IL-8 arose as an essential factor of angiogen-
esis and increased vascular permeability (58). Indeed, IL-8 can
provoke VEGF-R2 phosphorylation and transactivation, which in
turn result in both Src and RhoA activation, leading to endothe-
lial gap formation, and elevated permeability (59). IL-8 can also
increase permeability in mouse and human endothelial cells via a
VEGF-R2 independent mechanism (60). IL-8 initiates a signaling
route through CXCR2/Rac/PI3Kγ that triggers the phosphory-
lation and subsequent internalization of VE-cadherin, thereby
promoting increased permeability. Moreover, blockade of CXCR2
and PI3Kγ with pharmacological inhibitors or by RNA interfer-
ence (RNAi), limits IL-8-induced neovascularization and vessel
leakage (60). In glioblastoma, cancer cells were found to secrete
high concentrations of IL-8, which was further demonstrated to
function as a key factor involved in tumor-induced permeabil-
ity in vitro, and to signal to brain microvascular endothelial cells
via CXCR2, promotingVE-cadherin cell–cell junction remodeling,
and elevated permeability (61). Similarly, in prostate cancers, IL-8
secretion is associated with increased Akt expression and activa-
tion, which impacts on endothelial cell survival, angiogenesis, and
cell migration (62).
TRANSFORMING GROWTH FACTOR-β1
TGF-β1 is a multifunctional polypeptide member of the trans-
forming growth factor beta superfamily. It regulates the pro-
duction of cytokines and ECM components, and is involved in
diverse biological processes, such as proliferation and differen-
tiation in many cell types (63–65). Within the tumor microen-
vironment, macrophages, mesenchymal, and cancer cells secrete
TGF-β1 under hypoxic and inflammatory conditions. TGF-β1
was suggested to act as a potent inducer of angiogenesis, since
its increased expression correlates with high microvessel density
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FIGURE 4 | Molecular pathways involved inVEGF-endothelial
permeability. VEGF-A stimulation induces VEGF-R2 dimerization and
the sequential activation of Vav2, Rac, and PAK, through Src. This results
in the serine phosphorylation of VE-cadherin by PAK, and its subsequent
internalization into clathrin-coated pits. VEGF can also trigger the
tyrosine phosphorylation of VE-cadherin and of its binding partners
β-catenin (β-cat) and p120, in a Src-dependent fashion. In addition,
VEGF-A decreases the VE-cadherin/p120-catenin association and
promotes VE-cadherin endocytosis. VEGF-A also induces the
phosphorylation of myosin light chains (MLC), which produces stress
fibers that exert tension on intercellular junctions, thus weakening
cell–cell contacts. Finally, VEGF-A stimulation causes the dissociation of
VE-PTP/VE-cadherin and triggers loss of adhesion and permeability
increase.
and poor prognosis in various types of cancers (66). TGF-β1
also augments vascular permeability by altering cell–cell contacts.
This is thought to involve p38 mitogen-activated protein kinase
(MAPK) and RhoA signaling cascades, which in turn modulate
ECM adhesion and lead to the loss of endothelial-barrier integrity
and function (67). In primary breast tumors, TGF-β1 activity
is associated with an increased risk of lung metastasis. Indeed,
angiopoietin-related protein 4 (ANGPTL4), a TGF-β1 target gene,
disrupts endothelial cell–cell junctions, and facilitates the extrava-
sation of breast cancer cells (68). Moreover, TGF-β1 induces
the expression of VEGF in fibroblasts (69), whereas it inhibits
angiopoietin-1, an anti-permeability factor, therefore exacerbat-
ing tumor-associated vascular leakage (70). In addition, TGF-β1
potentiates the secretion and activation of MMPs (71).
STROMAL CELL-DERIVED FACTOR 1
Stromal cell-derived factor 1, also known as CXCL12, is a mem-
ber of the α-chemokine subfamily and the ligand for the GPCR
CXCR4. In adulthood, SDF-1 was implicated in angiogenesis by
recruiting endothelial progenitor cells from the bone marrow (72).
SDF-1 is highly expressed in a number of cancers and is associ-
ated with tumor extravasation and increased metastases (73, 74).
CXCR4 expression also corroborates with metastatic properties
of breast cancer cells (75). Indeed, CXCR4 levels were found to
be higher in malignant breast tumors in comparison to those of
normal healthy counterparts. In vivo, neutralizing CXCR4/SDF-1
signaling axis significantly impaired breast cancer cell extravasa-
tion and propagation (75, 76). SDF-1 can also mediate endothelial
permeability via CXCR4, as for instance, SDF-1 stimulation of
breast cancer cells in vitro increased their passage across the
endothelial barrier. This effect is dependent on both PI3K/Akt and
calcium signaling in endothelial cells (77). Inhibiting this pathway
with anti-CXCR4 antibodies, on the other hand, decreased vas-
cular leakage (77). Moreover, SDF-1 is involved in macrophage
recruitment to breast tumors in mice, in response to chemother-
apy (78). This action is believed to stimulate tumor blood vessel
growth, counteracting the effects of the drug. Finally, it is to be
noted that VEGF stimulates SDF-1 secretion and vice versa (79,
80). However, VEGF implication in SDF-1-induced permeability
remains to be elucidated.
INTERLEUKIN-10
IL-10, also known as human cytokine synthesis inhibitory factor,
is an anti-inflammatory cytokine. The role of IL-10 in cancers,
though well accepted, is vaguely understood (81). Indeed, IL-10
is suspected to exert both pro- and anti-tumor activities, and
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contradictory results have been reported regarding its involve-
ment in tumor angiogenesis. On one hand, IL-10 could hamper
angiogenesis and tumor growth in mice bearing VEGF-producing
ovarian cancer (82), and suppress tumor growth and metastasis of
human melanoma cells (83). On the other hand, other studies have
suggested that IL-10 may promote angiogenesis in a melanoma cell
model, by inhibiting macrophage functions and inducing tumor
and vascular cell proliferation (84).
MATRIX METALLOPROTEINASES
Metalloproteinases are a large family of proteases that include
MMP and ADAM (a disintegrin and metalloproteinase). MMPs
belong to a family of zinc-containing endopeptidases that degrade
various components of the ECM. Their aberrant over-expression
correlates with cancer progression, cell invasion, and metastasis
(85). Tumor-associated macrophages secrete VEGF and MMP-9,
which are directly involved in both breast cancer and colorectal
cancer cell invasion and metastasis (86). In addition, MMPs pro-
mote tumor progression by rearrangement of the ECM. Indeed,
they trim cell adhesion molecules and degrade matrix proteins,
favoring cell proliferation, and angiogenesis. MMP-7 can shed VE-
cadherin, while MMP-2 and MMP-9 are involved in occludin pro-
teolysis, thus enhancing endothelial permeability (87, 88). MMPs
can also potentiate vascular leakage in a more indirect fashion,
via cleavage and activation of chemokines such as IL-8, which is
processed by MMP-9 (89, 90). Moreover, in vitro experiments have
demonstrated a role for ADAM10 and ADAM17 in endothelial
gap formation in response to cytokines. This is probably mediated
by the cleavage of adhesion molecules within cell–cell junctions,
including VE-cadherin and JAM-A (91).
SEMAPHORINS
Semaphorins correspond to a family of secreted and membrane-
bound proteins that can act as both attractive and repulsive
guidance molecules (92, 93). Besides their role in neural develop-
ment, some of these molecules can modulate endothelial plasticity
(94). Indeed, semaphorin 4D plays a positive role in endothelial
migration and tumor angiogenesis (95, 96). In contrast, class 3
semaphorins, notably semaphorin 3A (S3A), and semaphorin 3E,
are reported to operate as selective inhibitors of VEGF-induced
angiogenesis (97–100). However, S3A and VEGF can also coop-
erate to induce vascular permeability (101). Indeed, S3A induces
Akt phosphorylation through PI3K signaling, thus enhancing vas-
cular permeability (101). In glioblastoma, the cancer stem-like cell
sub-population expresses and secretes S3A ex vivo (102). In this
context, S3A mediates endothelial cell–cell junction destabiliza-
tion and elevates endothelial permeability (102). On a molecular
level, S3A disrupts the VE-cadherin/PP2A complex, allowing VE-
cadherin serine phosphorylation and subsequent internalization
(45, 102). Consistent with this, inhibition of S3A by blocking anti-
body or by silencing RNAs has been demonstrated to abrogate
these effects.
NITRIC OXIDE AND PEROXYNITRITE
Nitric oxide (NO) is a highly reactive free radical, which medi-
ates a myriad of cellular reactions (103). NO is produced from
l-arginine and oxygen by NO synthases (NOS). There are three
major NOS isoforms: inducible NO synthase (NOS2/iNOS),eNOS
(NOS3/eNOS), and neuronal NO synthase (NOS1/nNOS). NOS3
is constitutively expressed in endothelial cells, cardiac myocytes,
and hippocampal pyramidal cells and is involved in suppressing
platelet aggregation, maintaining vascular tone, inhibiting smooth
muscle cell proliferation, and prompting angiogenesis (104). In
cancers, NOS3 generates NO in blood vessels, which can favor
endothelial proliferation, migration, and tumor progression (105,
106). Of note, NOS3 can be induced by VEGF in a MAPK/PLC-
γ-dependent manner (107). NOS3 may also be involved in mod-
ulating vascular leakage. Indeed, it has been reported that eNOS
translocation to the cytosol, but not to the Golgi, is associated
with hyperpermeability in vitro and in vivo (108, 109). Stimu-
lation of endothelial cells with platelet-activating factor (PAF)
induces S-nitrosylation of β-catenin and p120 and significantly
diminishes their association with VE-cadherin (110). Further-
more, VEGF treatment elicited S-nitrosylation of β-catenin at the
Cys619 residue, within the VE-cadherin interaction site (111).
Inhibition of β-catenin S-nitrosylation prevents NO-dependent
dissociation of β-catenin from VE-cadherin and disassembly of AJ
complexes, thereby inhibiting VEGF-mediated endothelial perme-
ability (111). Moreover, oxidized products of NO, such as perox-
ynitrite (ONOO-), activate MMPs, which favor matrix rearrange-
ment and endothelial permeability as discussed above. However,
NO can induce cytotoxic effects on cancer cells. The balance
between NO-mediated permeability and angiogenesis or apoptosis
should thus be considered in tumor-targeted therapy (112).
In conclusion, endothelial permeability-mediated signaling
pathways converge at the disruption and destabilization of cell–
cell contacts, promoting AJ and TJ restructuration and subsequent
opening of endothelial cell–cell junctions. We will now present
the anti-permeability factors and normalization agents that may
represent new perspectives in cancer therapy.
PERSPECTIVES IN CANCER THERAPY
It is now well accepted that vascular permeability limits drug deliv-
ery thus restraining the efficacy of conventional therapies. New
approaches aim now at diminishing both excessive angiogenesis
and hyperpermeability. In this paragraph, perspectives in cancer
therapy, such as the use of anti-permeability factors and blood
vessel normalization agents will be discussed.
ANTI-PERMEABILITY FACTORS
The most relevant anti-permeability factors are angiopoietin-1
and its cognate receptor Tie2, sphingosine-1-phosphate (S1P), and
fibroblast growth factor (FGF) (Figure 5).
Angiopoeitin-1 is a potent pro-angiogenic factor with the
particularity of stabilizing blood vessels and counteracting
VEGF-induced vascular permeability (63, 113). As mentioned
above, VEGF elevates endothelial permeability via VE-cadherin
adhesion destabilization in a Src-dependent mechanism (41,
45). Angiopoietin-1 elicits a signaling pathway through Tie2
that promotes the sequestration of Src though mammalian
diaphanous (mDia) (114), thus hindering VEGF signaling and
VE-cadherin internalization. In an intact endothelial monolayer,
angiopoietin-1 promotes the interaction of Tie2 with the vas-
cular endothelial protein tyrosine phosphatase VE-PTP (115,
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FIGURE 5 | Signaling pathways of anti-permeability factors. The most
relevant anti-permeability factors are angiopoietin-1 (Ang1), sphingosine-1-
phosphate (S1P), and fibroblast growth factor (FGF). Ang1 activation of its
cognate receptor, Tie2, elicits a signaling pathway and promotes Src
sequestration; thus hindering VEGF-A signaling and VE-cadherin
internalization. S1P signaling maintains vascular integrity by modulating
VE-cadherin internalization, cytoskeletal rearrangement, barrier enhancement
and integrity, through its cognate receptor S1P1R. FGF maintains the integrity
of the VE-cadherin/p120-catenin complex, thus stabilizing VE-cadherin at the
membrane.
116). VE-PTP associates with VE-cadherin and stabilizes it at
the plasma membrane by blocking its tyrosine phosphoryla-
tion in response to VEGF-R2 activation (117). Angiopoeitin-1
also maintains the barrier integrity by increasing the associa-
tion between VE-cadherin and plakoglobin (118), thus strength-
ening cell–cell contacts and limiting endothelial permeability.
Consistently, VEGF signaling in vivo triggers the dissociation of
VE-PTP from VE-cadherin, facilitating leukocyte extravasation
and vessel leakage (119). Furthermore, angiopoeitin-1 balances
VEGF pro-permeability actions by controlling NO release from
endothelial cells. Indeed, it increases eNOS phosphorylation on
Thr497,and subsequently reduces NO release and transendothelial
permeability (120).
In addition to angiopoeitin-1, S1P, a biologically active phos-
phorylated lipid growth factor released from activated platelets,
has emerged as an endothelial barrier protective agent. In both
pulmonary artery and lung microvascular endothelial cells, S1P
was able to reverse barrier dysfunctions elicited by thrombin (121).
At the molecular level, S1P signaling maintains vascular integrity
by cytoskeletal rearrangement and barrier enhancement through
Rac activation (121). Moreover, high-density lipoproteins, acting
as major plasma carriers for S1P, promote endothelial-barrier
integrity via the Akt signaling pathway (122). Plasma-derived
S1P also plays an essential role in maintaining vascular integrity.
Indeed, mutant mice engineered to selectively lack S1P in plasma
show increased vascular leak and impaired survival after admin-
istration of permeability inducing factors (123). Elevated leak
was associated with interendothelial cell gaps in venules and was
reversed by acute treatment with an agonist for the S1P receptor
1 (S1PR1) (123). Furthermore, recent works present S1PR1, as a
key component of vascular stability (124, 125). These two studies
elegantly showed that S1PR1 inhibits VEGF-induced VE-cadherin
destabilization and internalization, and thereby enhances cell–cell
adhesion (124, 125).
Other factors, such as FGF, can act as VE-cadherin stabilizing
agents. Indeed, the inhibition of FGF signaling results in the disso-
ciation of theVE-cadherin/p120-catenin complex, and subsequent
VE-cadherin internalization, disassembly of AJ and TJ, and loss of
vascular barrier integrity (126).
Thus, since they counteract VEGF-induced permeability and
contribute to the maintenance of vascular barrier function, anti-
permeability factors appear as potential therapeutic candidates.
Another promising approach is the use of anti-VEGF/VEGF-
R drugs to promote normalization of the vascular wall and its
microenvironment.
NORMALIZATION AGENTS
From 1950 to the 2000s, the only existing non-invasive treatment
for solid tumors has been chemotherapy, which is mainly based
on reducing tumor cell proliferation. Because its lack of selectivity
causes a large panel of side effects, new strategies, such as mole-
cular and personalized therapies, attempt to focus on molecules
overexpressed in cancers. Unfortunately, the results from clinical
trials targeting such molecules in anti-cancer therapy have been
quite disappointing with an overall low extension of survival, with
the exception of imatinib, a tyrosine kinase inhibitor (TKI) used in
chronic myelogenous leukemia treatment (127). In addition, anti-
angiogenic molecules have been suggested to improve anti-cancer
therapy, not only because they reduce tumor vascularization, but
also thanks to their “normalization” action, which improves drug
delivery.
Bevacizumab (commercialized as Avastin) was one of the first
clinically available anti-angiogenic drugs. This humanized mouse
antibody targeting VEGF was FDA-approved about a decade ago
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for combination use with standard chemotherapy in colorectal and
non-small cell lung cancers. In addition, bevacizumab alone can
significantly curb disease progression in patients with metastatic
renal cell cancer (128). Recently published data suggest promis-
ing clinical efficacy of bevacizumab monotherapy in metastatic
melanoma (129). Beside anti-VEGF, broad-spectrum multi-target
TKI prolong cancer-free survival by collectively decreasing tumor
vessel diameter, density, and permeability, even when admin-
istered in the absence of conventional therapies. For instance,
sunitinib and sorafenib monotherapies appear particularly effi-
cient in gastrointestinal and renal cancers (130). Nevertheless,both
bevacizumab and TKI can cause serious adverse effects, such as
gastrointestinal perforations.
The Notch ligand delta-like 4 (Dll4) has recently emerged as
a critical regulator of tumor angiogenesis (131). Activation of
the Notch pathway in neighboring endothelial cells causes inhi-
bition of tip cell formation, an early event in sprouting angio-
genesis. Mechanistically, this is believed to occur through the
down-regulation of VEGF-R2/3 pro-angiogenic pathway and the
up-regulation of VEGF-R1 anti-angiogenic pathway (132). Inter-
estingly, VEGF can also operate upstream of Dll4 to potentiate
its effects (133). However, the exact role of Dll4 in tumor growth
and its potential in anti-cancer therapy remain unclear. Indeed,
Dll4/Notch activation reduces overall tumor angiogenesis, while
tumor vascular function was improved and tumor growth was
heightened (134). This supports the notion that further strategy
in anti-cancer therapy could be based on Dll4/Notch signal-
ing blockade. On the other hand, Dll4-driven Notch activation
might reduce both tumor-induced angiogenesis and endothelial
cell responsiveness to VEGF (135), and therefore argue rather
for the use of Dll4 as an effective therapeutic approach in
cancers.
COMBINATION THERAPY AND FUTURE STRATEGIES
Recently, based on general hallmarks of the tumor vasculature, i.e.,
poor blood flow, leakage, and reduced drug uptake, a new trend in
anti-cancer treatment has emerged, that involves combining vas-
cular normalization agents with traditional therapies to improve
treatment response.
To re-establish an efficient tumor vascularization, assis-
tant molecules, namely those bearing anti-angiogenic or anti-
permeability properties, have been designed and tested in clinical
trials, in parallel with cytotoxic drugs. In this scenario, the use of
either the vasoconstrictor Angiotensin II (136) or the vasodilator
Bradykinin B2 receptor agonist (137) improves tumor treatment
uptake, through an increase in transcapillary pressure. Similarly,
to facilitate stromal barrier crossing, the ECM-degrading enzyme
collagenase (138) was shown to exert favorable changes in the tran-
scapillary pressure gradient and thereby enhance anti-cancer drug
penetration.
Alternatively, bevacizumab, the anti-VEGF drug, impinges
on both microvascular density and tumor IFP, and improves
drug uptake in colorectal carcinoma patients (139). Moreover,
pazopanib, an inhibitor of VEGF and PDGF receptors, induces
better tumor liposomal drug delivery (140). Likewise, radiother-
apy combined with anti-integrin antibody (intetumumab) reduces
tumor vessel density, while increasing tumor cell apoptosis and
hindering metastasis (141). Interestingly, apart from its role in
permeability, high levels of VEGF have been reported to pro-
mote T-reg proliferation, inhibit antigen-presenting cell matu-
ration and as a consequence, decrease immune responses (142,
143). Therefore, anti-angiogenic drugs, especially those targeting
VEGF actions, could improve cancer immunotherapy by stimulat-
ing tumor microenvironment immune responses (142). Although
significant evidence has demonstrated the benefits of anti-VEGF
therapies in cancer treatment, its general use is still controversial.
First, significant increase in overall survival is observed only when
bevacizumab is combined with standard chemotherapies. In addi-
tion, many patients exhibit resistance to anti-VEGF treatments,
while timing and doses to be administered, cost and relapse effects
raise some major concerns. Finally, vascular regrowth remains
highly problematic. Indeed, a second wave of angiogenesis orches-
trated by pro-angiogenic ligands of the FGF family could account
for the short-term efficacy of VEGF-based anti-angiogenic thera-
pies (144). Unlike bevacizumab, combination of TKI with conven-
tional chemotherapy does not improve the outcome of anti-cancer
treatment. In this scenario, use of erlotinib, a potent inhibitor
of the epidermal growth factor receptor tyrosine kinase, with
standard chemotherapy has failed to enhance tumor response or
survival in lung carcinoma (145). Highly efficient TKI monother-
apy could be combined with chemotherapy only when tumor cells
become resistant to TKIs.
Alternatively, dose, schedule, and decreased toxicity may
amend tumor responses. Contrary to standard chemotherapy,
i.e., high doses with prolonged drug-free breaks, metronomic
chemotherapy refers to chronic and equally spaced administra-
tion of low doses of cytotoxic drugs, without pauses. For example,
reduced but continuous doses of cyclophosphamide suppressed
tumor growth more effectively than canonical chemotherapy
scheduling, even in drug-resistant tumors (146). Interestingly,
metronomic chemotherapy exerts anti-tumor and anti-metastatic
actions by decreasing VEGF serum concentration and increas-
ing apoptosis of cancer cells (147). For those reasons, metro-
nomic chemotherapy could be considered as an anti-angiogenic
chemotherapy.
Importantly, the efficacy of anti-angiogenic therapy combined
with cytotoxic conventional therapies (chemo- and/or radio-
therapies) depends on optimal treatment scheduling. Indeed for
each anti-cancer therapy, a “normalization window,” has to be
determined to define period and doses necessary for tumor vessel
normalization (148).
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